|
시장보고서
상품코드
2084785
항응고제 시장 : 약제 클래스별, 용도별, 지역별Anticoagulant Market, By Drug Class, By Application, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
항응고제 시장은 2026년에 461억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 835억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 461억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 8.90% | 2033년 시장 규모 예측 : | 835억 달러 |
항응고제는 혈전 형성을 막아주는 약의 일종입니다. 일반적으로 '혈액 희석제'라고 불립니다. 혈전 발생 위험이 높은 사람에게 투여되어, 뇌졸중이나 심근경색 등 중증 질환이 발생할 가능성을 낮춥니다. 항응고제는 심혈관 질환(CVD)의 예방 및 치료에 널리 사용되고 있습니다.
시장 역학
만성질환 유병률의 증가, 항응고제에 대한 수요 증가, 신규 항응고제 개발에 대한 관심 고조, 그리고 전 세계적인 고령화 추세가 세계 항응고제 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다.
예를 들어 2022년 6월, 아포텍스(Apotex Inc.)는 캐나다에서 최초로 ‘엘리퀴스(Eliquis)’의 제네릭 의약품인 ‘APO-아피사반 정’의 출시를 발표했습니다. 아피사반은 유해한 혈전의 예방 및 치료에 사용되는 경구용 항응고제입니다.
또한 2021년 6월에는 미국 식품의약국(FDA)이 생후 3개월부터 12세까지의 소아를 대상으로 한 정맥혈전색전증 치료제로 ‘프라닥사(다비가트란 에텍시레이트)’ 경구용 펠릿 제제를 승인했습니다. 또한 FDA는 첫 번째 정맥 혈전색전증 치료를 마친 생후 3개월 이상 12세 미만의 환자에서 혈전 재발 예방을 위한 '프라닥사' 경구용 펠릿도 승인했습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 기업의 주요 정보, 제품 포트폴리오, 주요 성과, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 항응고제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 항응고제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 항응고제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 항응고제 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 항응고제 시장 : 용도별, 2021-2033년
제6장 세계의 항응고제 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.07.14Anticoagulant Market is estimated to be valued at USD 46.1 Bn in 2026 and is expected to reach USD 83.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 46.1 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.90% | 2033 Value Projection: | USD 83.5 Bn |
Anticoagulants are a class of drugs that help prevent blood clots. They are commonly called blood thinners. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. Anticoagulants are commonly used to prevent and treat cardiovascular diseases (CVDs).
Market Dynamics
Growing prevalence of chronic disease, rise in demand for anticoagulants, increase in focus on the development of novel anticoagulants, and growing geriatric population across the globe are major factors expected to drive growth of the global anticoagulant market.
For instance, in June 2022, Apotex Inc. announced the launch of APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots.
Moreover, in June 2021, the Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets to treat children three months to 12 years old with venous thromboembolism. FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global anticoagulant market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Sanofi SA, Dr. Reddy's Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global anticoagulant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulant market.
Market Segmentation
- By Drug Class (Revenue, USD Bn, 2021-2033)
- Novel Oral Anticoagulants (NOACs)
- Heparin and Low-molecular- weight Heparin (LMWH)
- Vitamin K Antagonist
- By Application (Revenue, USD Bn, 2021-2033)
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Other Applications
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Pfizer Inc.
- Sanofi SA
- Reddy's Laboratories
- Aspen Holdings
- Abbott Laboratories
- Leo Pharma AS
- Alexion Pharmaceuticals Inc.
- Bayer AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Boehringer Ingelheim Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Anticoagulant Market, By Drug Class, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Novel Oral Anticoagulants (NOACs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Heparin and Low-molecular- weight Heparin (LMWH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Vitamin K Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Anticoagulant Market, By Application, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Other Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Anticoagulant Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Dr. Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aspen Holdings
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Leo Pharma AS
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Alexion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Daiichi Sankyo Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Boehringer Ingelheim Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
